Nektar Therapeutics (NASDAQ:NKTR) was the target of some unusual options trading on Thursday. Stock traders purchased 4,211 call options on the company. This represents an increase of Infinity compared to the average volume of 0 call options.

In related news, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $32,863.32. Following the sale, the senior vice president now owns 31,102 shares of the company’s stock, valued at approximately $600,890.64. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Stephen K. Doberstein sold 396,323 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total value of $11,493,367.00. Following the completion of the sale, the senior vice president now directly owns 52,016 shares in the company, valued at approximately $1,508,464. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,024,757 shares of company stock worth $25,974,361. 5.44% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. Arizona State Retirement System raised its position in shares of Nektar Therapeutics by 1.0% during the second quarter. Arizona State Retirement System now owns 80,945 shares of the biopharmaceutical company’s stock worth $1,582,000 after acquiring an additional 800 shares during the last quarter. State of Wisconsin Investment Board bought a new stake in shares of Nektar Therapeutics during the second quarter worth $2,248,000. Bank of New York Mellon Corp raised its position in shares of Nektar Therapeutics by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after acquiring an additional 12,730 shares during the last quarter. Ameriprise Financial Inc. raised its position in shares of Nektar Therapeutics by 9.1% during the second quarter. Ameriprise Financial Inc. now owns 952,443 shares of the biopharmaceutical company’s stock worth $18,620,000 after acquiring an additional 79,510 shares during the last quarter. Finally, Piedmont Investment Advisors LLC raised its position in shares of Nektar Therapeutics by 264.6% during the second quarter. Piedmont Investment Advisors LLC now owns 33,545 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 24,344 shares during the last quarter. Institutional investors own 94.97% of the company’s stock.

Several brokerages recently commented on NKTR. Jefferies Group LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, July 21st. Roth Capital set a $33.00 price target on Nektar Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. Cowen and Company began coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating on the stock. Canaccord Genuity began coverage on Nektar Therapeutics in a research note on Thursday, November 9th. They issued a “buy” rating and a $35.00 price target on the stock. Finally, BidaskClub lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and an average target price of $31.82.

Nektar Therapeutics (NASDAQ:NKTR) opened at $37.10 on Tuesday. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a one year low of $11.41 and a one year high of $41.34.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. The company had revenue of $152.90 million during the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The firm’s quarterly revenue was up 321.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.32) earnings per share. analysts anticipate that Nektar Therapeutics will post -0.78 EPS for the current year.

WARNING: “Investors Buy Large Volume of Call Options on Nektar Therapeutics (NKTR)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2017/11/13/investors-buy-large-volume-of-call-options-on-nektar-therapeutics-nktr.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.